拉帕替尼-话题@MedSci

#拉帕替尼#

26篇内容 | 1011人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1441549, encodeId=57561441549ab, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, objectType=article, longId=217525, objectId=c79c21e52563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c79c21e52563, replyNumber=0, likeNumber=32, createdTime=2021-09-25, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c79c21e52563, moduleTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c79c21e52563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441548, encodeId=22b31441548bc, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, objectType=article, longId=217280, objectId=228d21e2804b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=228d21e2804b, replyNumber=0, likeNumber=55, createdTime=2021-09-20, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=228d21e2804b, moduleTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=228d21e2804b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441547, encodeId=ef30144154e37, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=Eur J Cancer：拉帕替尼和曲妥珠单抗同步治疗HER2+乳腺癌可的预后, objectType=article, longId=214775, objectId=19d2214e7562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19d2214e7562, replyNumber=0, likeNumber=41, createdTime=2021-07-26, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19d2214e7562, moduleTitle=Eur J Cancer：拉帕替尼和曲妥珠单抗同步治疗HER2+乳腺癌可的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19d2214e7562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441546, encodeId=2f1814415463a, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=Eur J Cancer：曲妥珠单抗-拉帕替尼新辅助治疗HER2+早期乳腺癌患者的疗效：来自CHER-Lob研究, objectType=article, longId=214418, objectId=1d9b21441830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d9b21441830, replyNumber=0, likeNumber=38, createdTime=2021-07-21, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d9b21441830, moduleTitle=Eur J Cancer：曲妥珠单抗-拉帕替尼新辅助治疗HER2+早期乳腺癌患者的疗效：来自CHER-Lob研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d9b21441830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441545, encodeId=3c2314415450e, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=拉帕替尼不良反应管理共识, objectType=article, longId=185310, objectId=9def1853108f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9def1853108f, replyNumber=0, likeNumber=18, createdTime=2019-12-28, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9def1853108f, moduleTitle=拉帕替尼不良反应管理共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9def1853108f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441544, encodeId=835c1441544d7, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=J Cell Biochem：拉帕替尼和紫杉醇的单独或联合治疗会导致骨质流失和骨髓脂肪化, objectType=article, longId=150629, objectId=63851506291d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63851506291d, replyNumber=0, likeNumber=32, createdTime=2018-10-10, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63851506291d, moduleTitle=J Cell Biochem：拉帕替尼和紫杉醇的单独或联合治疗会导致骨质流失和骨髓脂肪化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63851506291d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441543, encodeId=6424144154331, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析, objectType=article, longId=132605, objectId=9efd13260523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9efd13260523, replyNumber=0, likeNumber=0, createdTime=2018-03-18, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9efd13260523, moduleTitle=JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9efd13260523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441542, encodeId=5ef8144154285, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=Ann Oncol：HER2+胃癌患者或是拉帕替尼治疗的获益人群, objectType=article, longId=130602, objectId=f26c13060202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26c13060202, replyNumber=0, likeNumber=22, createdTime=2018-02-27, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26c13060202, moduleTitle=Ann Oncol：HER2+胃癌患者或是拉帕替尼治疗的获益人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f26c13060202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441541, encodeId=95ec14415412c, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=J Clin Oncol：拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌, objectType=article, longId=129990, objectId=5260129990bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5260129990bd, replyNumber=0, likeNumber=34, createdTime=2018-02-16, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5260129990bd, moduleTitle=J Clin Oncol：拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5260129990bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441540, encodeId=d75b14415402a, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, objectType=article, longId=124477, objectId=e6f71244e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f71244e794, replyNumber=0, likeNumber=29, createdTime=2017-12-26, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f71244e794, moduleTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f71244e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441539, encodeId=9f94144153938, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=殷咏梅教授：曲妥珠单抗失败后，续用曲妥珠单抗与换用拉帕替尼之争, objectType=article, longId=122491, objectId=b6491224911d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6491224911d, replyNumber=0, likeNumber=41, createdTime=2017-12-08, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6491224911d, moduleTitle=殷咏梅教授：曲妥珠单抗失败后，续用曲妥珠单抗与换用拉帕替尼之争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6491224911d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441538, encodeId=fc201441538ae, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=Oncologist：食管癌新辅助方案中加入拉帕替尼是否可行？, objectType=article, longId=108033, objectId=2e571080330d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e571080330d, replyNumber=0, likeNumber=39, createdTime=2017-08-09, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e571080330d, moduleTitle=Oncologist：食管癌新辅助方案中加入拉帕替尼是否可行？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e571080330d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441537, encodeId=f75d144153e30, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=JAMA Oncology：哪种患者可从曲妥珠单抗vs拉帕替尼中获益最多？, objectType=article, longId=107568, objectId=cbe610e56822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe610e56822, replyNumber=0, likeNumber=34, createdTime=2017-08-05, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe610e56822, moduleTitle=JAMA Oncology：哪种患者可从曲妥珠单抗vs拉帕替尼中获益最多？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe610e56822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441536, encodeId=d06f144153616, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=J Clin Oncol：HER1/HER2-阳性转移性UBC患者一线化疗后：拉帕替尼vs安慰剂, objectType=article, longId=95505, objectId=bd6c9550523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd6c9550523, replyNumber=0, likeNumber=31, createdTime=2017-04-13, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd6c9550523, moduleTitle=J Clin Oncol：HER1/HER2-阳性转移性UBC患者一线化疗后：拉帕替尼vs安慰剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd6c9550523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441535, encodeId=6f7c1441535ff, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=JCO：HER2阳性乳腺癌化疗——拉帕替尼并不优于曲妥单抗，反而增加了药毒性, objectType=article, longId=60124, objectId=d131601246f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d131601246f, replyNumber=0, likeNumber=34, createdTime=2015-12-05, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d131601246f, moduleTitle=JCO：HER2阳性乳腺癌化疗——拉帕替尼并不优于曲妥单抗，反而增加了药毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d131601246f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441534, encodeId=c1f81441534a4, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间, objectType=article, longId=60099, objectId=b5e3600995e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e3600995e, replyNumber=0, likeNumber=44, createdTime=2015-12-05, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e3600995e, moduleTitle=JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e3600995e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, objectType=article, longId=56015, objectId=17c9560153c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17c9560153c, replyNumber=0, likeNumber=23, createdTime=2015-09-11, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17c9560153c, moduleTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17c9560153c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441532, encodeId=921d144153269, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=JCO：早期拉帕替尼联用曲妥单抗对HER2+乳腺癌效果更优, objectType=article, longId=53352, objectId=0f17533529c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f17533529c, replyNumber=0, likeNumber=15, createdTime=2015-07-16, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f17533529c, moduleTitle=JCO：早期拉帕替尼联用曲妥单抗对HER2+乳腺癌效果更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f17533529c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441531, encodeId=e871144153168, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=JCO：拉帕替尼+希罗达VS赫赛汀+希罗达用于Her-2阳性转移性乳腺癌, objectType=article, longId=46602, objectId=d54d466020a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d54d466020a, replyNumber=0, likeNumber=38, createdTime=2015-02-05, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d54d466020a, moduleTitle=JCO：拉帕替尼+希罗达VS赫赛汀+希罗达用于Her-2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d54d466020a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441530, encodeId=64e41441530bd, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, objectTitle=ASCO 2014：高危头颈部鳞状细胞癌辅助术后拉帕替尼同步放化疗不增加DFS, objectType=article, longId=35256, objectId=6ba335256be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ba335256be, replyNumber=0, likeNumber=35, createdTime=2014-05-25, rootId=0, userName=ms9474365431325850, userId=7acb4863797, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ba335256be, moduleTitle=ASCO 2014：高危头颈部鳞状细胞癌辅助术后拉帕替尼同步放化疗不增加DFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ba335256be)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

拉帕替尼

2020-05-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索

2021-09-25

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究

2021-09-20

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

Eur J Cancer：拉帕替尼和曲妥珠单抗同步治疗HER2+乳腺癌可的预后

2021-07-26

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

Eur J Cancer：曲妥珠单抗-拉帕替尼新辅助治疗HER2+早期乳腺癌患者的疗效：来自CHER-Lob研究

2021-07-21

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

拉帕替尼不良反应管理共识

2019-12-28

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

J Cell Biochem：拉帕替尼和紫杉醇的单独或联合治疗会导致骨质流失和骨髓脂肪化

2018-10-10

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析

2018-03-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

Ann Oncol：HER2+胃癌患者或是拉帕替尼治疗的获益人群

2018-02-27

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

J Clin Oncol：拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌

2018-02-16

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌

2017-12-26

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

殷咏梅教授：曲妥珠单抗失败后，续用曲妥珠单抗与换用拉帕替尼之争

2017-12-08

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

Oncologist：食管癌新辅助方案中加入拉帕替尼是否可行？

2017-08-09

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

JAMA Oncology：哪种患者可从曲妥珠单抗vs拉帕替尼中获益最多？

2017-08-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

J Clin Oncol：HER1/HER2-阳性转移性UBC患者一线化疗后：拉帕替尼vs安慰剂

2017-04-13

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

JCO：HER2阳性乳腺癌化疗——拉帕替尼并不优于曲妥单抗，反而增加了药毒性

2015-12-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间

2015-12-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究

2015-09-11

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

JCO：早期拉帕替尼联用曲妥单抗对HER2+乳腺癌效果更优

2015-07-16

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

JCO：拉帕替尼+希罗达VS赫赛汀+希罗达用于Her-2阳性转移性乳腺癌

2015-02-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#拉帕替尼#

ASCO 2014：高危头颈部鳞状细胞癌辅助术后拉帕替尼同步放化疗不增加DFS

2014-05-25

科室
- - 订阅+
  - 更多科室
工具
服务